Top Suppliers:I want be here
Hot CAS#:
56-41-7 108-65-6
56-35-9 64-17-5
67-56-1 108-88-3
141-78-6 1310-73-2
13463-67-7 1333-86-4

28434-74-4

28434-74-4 structure
28434-74-4 structure
  • Name: sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate
  • Chemical Name: sodium,3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate
  • CAS Number: 28434-74-4
  • Molecular Formula: C17H19N2NaO5S
  • Molecular Weight: 386.39800
  • Catalog: Signaling Pathways Membrane Transporter/Ion Channel NKCC
  • Create Date: 2017-07-29 19:16:17
  • Modify Date: 2024-01-07 11:06:56
  • Bumetanide sodium, a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide sodium is a selective NKCC1 inhibitor, and also inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively[1][2].
Name sodium,3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate
Synonyms Sodium 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoate
Sodium 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate
Benzoic acid,3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-,sodium salt (1:1)
SODIUM 3-(AMINOSULFONYL)-5-(BUTYLAMINO)-4-PHENOXYBENZOATE
Benzoic acid,3-(butylamino)-4-phenoxy-5-sulfamoyl-,monosodium salt (8CI)
EINECS 249-015-6
sodium bumetanide
Benzoicacid,3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-,monosodium salt (9CI)
Description Bumetanide sodium, a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide sodium is a selective NKCC1 inhibitor, and also inhibits NKCC2, with IC50s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively[1][2].
Related Catalog
In Vitro Bumetanide sodium has inhibitory effects for the two major human splice variants of NKCCs, hNKCC1A and hNKCC2A [1]. Bumetanide sodium (0.03-100 μM; 5 minutes) inhibits the 86Rb+ uptake in NKCC1A-expressing oocytes in a dose-dependent manner[1]. Bumetanide sodium inhibits NKCC2 isoform B in HEK-293 cells with an IC50 value of 0.54 μM[2].
In Vivo Bumetanide sodium (7.6-30.4 mg/kg; i.v.) attenuates the decrease in apparent diffusion coefficients (ADC) ratios for both cortex and striatum (by 40-67%), indicating reduced edema formation[3]. Bumetanide sodium also reduces infarct size[3]. Bumetanide sodium shows different half-lives of 21.4 min, 53.8 min and 137 min following 2 mg/kg, 8 mg/kg and 20 mg/kg intravenous injection, respectively, in rats[4].
References

[1]. Lykke K, et al. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A. Epilepsy Behav. 2016 Jun;59:42-9.

[2]. Ciaran Richardson, et al. Regulation of the NKCC2 ion cotransporter by SPAK-OSR1-dependent and -independent pathways. J Cell Sci. 2011 Mar 1;124(Pt 5):789-800.

[3]. Martha E O'Donnell, et al. Bumetanide inhibition of the blood-brain barrier Na-K-Cl cotransporter reduces edema formation in the rat middle cerebral artery occlusion model of stroke. J Cereb Blood Flow Metab. 2004 Sep;24(9):1046-56.

[4]. S H Lee, et al. Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokinet Biopharm. 1994 Feb;22(1):1-17.6
Boiling Point 571.2ºC at 760mmHg
Molecular Formula C17H19N2NaO5S
Molecular Weight 386.39800
Flash Point 299.3ºC
Exact Mass 386.09100
PSA 129.93000
LogP 3.55590
Vapour Pressure 6.89E-14mmHg at 25°C
Precursor  1

DownStream  0


Chemsrc provides CAS#:28434-74-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 28434-74-4 | Chemsrc address: https://www.chemsrc.com/en/baike/874502.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved